Baumann et al., 2003 - Google Patents
Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after …Baumann et al., 2003
- Document ID
- 3278064053616374913
- Author
- Baumann M
- Krause M
- Zips D
- Eicheler W
- Dörfler A
- Ahrens J
- Petersen C
- Brüchner K
- Hilberg F
- Publication year
- Publication venue
- International journal of radiation biology
External Links
Snippet
Purpose: To investigate the effect of BIBX1382BS, an inhibitor of the epidermal growth factor receptor tyrosine kinase, on proliferation and clonogenic cell survival of FaDu human squamous cell carcinoma in vitro, and on tumour growth and local tumour control after …
- 101700039191 EGFR 0 title abstract description 56
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baumann et al. | Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse | |
| CN104363913B (en) | CDK8/CDK19 selective depressants and its purposes in the anti-rotation shifting of cancer and chemoprophylaxis method | |
| US11911469B2 (en) | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | |
| AU2015289504B2 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| JP2020158507A6 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and chemotherapeutic agents | |
| JP2008500338A (en) | Method for treating and / or preventing abnormal proliferation of hematopoietic cells | |
| CA3222772A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| KR20200040763A (en) | Targeting kinase for the treatment of cancer metastasis | |
| US11571400B2 (en) | ACAT1 inhibitors for treating cancer | |
| Grzmil et al. | Deregulated signalling networks in human brain tumours | |
| Zhang et al. | Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model | |
| JP2025024030A (en) | Alkyl TPP Compounds for Mitochondrial Targeting and Anticancer Therapy | |
| Gogineni et al. | α3β1 integrin promotes radiation-induced migration of meningioma cells Retraction in/10.3892/ijo. 2021.5189 | |
| WO2008078109A2 (en) | Medicament | |
| Nakata et al. | S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU | |
| CN105189786A (en) | FALZ for use as a target for therapies to treat cancer | |
| CN111132672A (en) | Treatment of drug-resistant gliomas | |
| US20180289676A1 (en) | Compounds and methods targeting gper in cancer | |
| Panek et al. | P08. 46 Synergistic Therapeutic Efficacy via Immunomodulatory Platelet Rich Fibrin Patch (PRF-P) in Combination with Oncolytic Adenovirus for the Treatment of Glioma | |
| JP7098054B2 (en) | 2,3,5-Substituted thiophene compound for promoting radiotherapy | |
| Filipova et al. | Clinical Radiobiology for Radiation | |
| Suri et al. | EXTH-08. DEVELOPMENT OF NOVEL HISTONE DEMETHYLASE INHIBITOR AGAINST DIPG | |
| Tsukumo et al. | MTOR and regulation of translation | |
| US20220218801A1 (en) | Combination gmci and atri cancer treatment | |
| Sahoo et al. | TMOD-01. THE ROLE OF PERSISTENCE, PROLIFERATION, AND TUMOR CELL KILLING EFFICIENCY IN DETERMINING RESPONSE TO CAR T-CELL THERAPY IN GLIOBLASTOMA: A MATHEMATICAL MODEL AND ANALYSIS |